Healthcare / BiotechnologyStockholm
$1.59
+0.17 (+11.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-6.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-116.1%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.7%
FCF CAGR
—
FCF margin
-588.6%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.1M · net income $-17.0M · FCF $-6.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1M | $1.1M | $774889.00 | $1.5M | $1.9M |
| Net Income | $-17.0M | $-17.0M | $-11.2M | $-9.9M | $-26.8M |
| EBITDA | $-15.9M | $-15.9M | $-10.2M | $-8.8M | $-26.8M |
| EPS | — | — | -0.44 | -0.42 | -1.38 |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Operating Margin | -713.0% | -713.0% | -1046.5% | -437.0% | -472.7% |
| Net Margin | -1509.0% | -1509.0% | -1450.7% | -678.7% | -1423.7% |
| Balance Sheet | |||||
| Current Ratio | 10.27 | 10.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.6M | $-6.6M | $-7.8M | $-4.9M | $-9.1M |
| Returns | |||||
| ROE | -116.1% | -116.1% | -213.7% | -149.1% | -281.0% |
| Valuation | |||||
| P/B | 4.58 | 4.58 | 21.78 | 7.00 | 6.63 |
| Growth & Yield | |||||
| Revenue Growth | 45.4% | 45.4% | -47.0% | -22.2% | — |
| EPS Growth | — | — | -5.0% | 69.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.44 → n/d
Residual
-46.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.